Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

DEA Issues Policy Statement On Changes a Pharmacist Can Make to a Schedule II paper Prescription

Posted 10/19/2022

On October 18, 2022 DEA posted the attached policy statement on its Diversion website regarding changes a pharmacist may make to a Schedule II paper prescription. In its statement, DEA defers to state regulations or policy until it can provide changes to its regulations to address the issue.

Title: Changes Pharmacists May Make to Schedule II Paper Prescriptions

Summary: This guidance document provides clarification regarding the changes pharmacists may make to schedule II paper prescriptions. This guidance will remain in effect until the Drug Enforcement Administration (DEA) codifies new regulations, or until this guidance is otherwise modified or withdrawn by DEA. This guidance will be sent via email to all DEA-registered pharmacies and practitioners and will be posted on the DEA guidance portal.

Activity: Changes Pharmacist May Make to Schedule II Paper Prescriptions

To Whom It Applies: All DEA-Registered Pharmacies and Practitioners

Question: What changes can be made to a schedule II paper prescription?

Answer: In the past few months, DEA has received an increasing number of questions concerning pharmacists? ability to add or modify information?like a patient?s address?on paper prescriptions. To address these questions, DEA has been reviewing the relevant regulations and working to draft new regulations to address this issue. In the interim, pharmacists should adhere to state regulations or policy regarding those changes that a pharmacist may make to a schedule II prescription after oral consultation with the prescriber.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way. This document is intended only to provide clarity to the public regarding existing requirements under the law or Department of Justice policies.

EO-DEA257, DEA-DC-063, October 18, 2022

Text here 

Back to all news

Sponsor Spotlight


Bamboo Health
Prescription Drug Monitoring Programs (PDMPs) are critical to the mission of the National Association of State Controlled Substances Authorities (NASCSA), helping to prevent the misuse and diversion of controlled substances. Bamboo Health provides the nation’s most comprehensive prescription drug monitoring program (PDMP) solutions through our years of experience with partnerships across 44 unique PDMPs. Bamboo Health's advanced analytics, real-time clinical decision support, and critical insights and interventions support more than 1.6 million physicians, pharmacists, and care team members across hundreds of millions of patients encounters each year.

Our solutions have demonstrated leadership and continued support of state PDMP innovations designed to maximize the effectiveness of the PDMP for its users. Our solutions include the ability to add clinical tools such as clinical alerts, intuitive data graphs, peer-to-peer messaging which enable prescribers and pharmacists to better evaluate PDMP reports. In addition, Bamboo Health’s PDMP integration protocol through the PMP Gateway solution supports an estimated 1 billion patient queries annually across 48 states. States who adopt our statewide integration solution realize a 6-8-fold increase in PDMP queries while significantly improving user satisfaction. As responsible leaders in this market, we are proud to partner with our State PDMP partners to continue to innovate and enhance our solutions to deliver on this mission, ensuring that we get the right information in front of the right clinicians, at the right time, and in the right place. For more information visit www.Bamboohealth.com

All Sponsors